• Oncoclinicas shareholders approved a seven-member board and its single slate at an extraordinary meeting on November 6, 2026.
• All seven board nominees were approved as independent directors.
• Shareholders endorsed Marcelo Curti as board chairman and Hélio Paulo Ferraz as vice chairman.
• Votes favored requesting cumulative voting and equal allocation among slate members if that method was adopted; abstentions dominated both questions.
• Shareholders rejected allowing votes to remain assigned to the slate if a candidate withdrew.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncoclinicas do Brasil Servicos Medicos SA published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.